Literature DB >> 8675681

Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein AI gene.

D R Booth1, S Y Tan, S E Booth, G A Tennent, W L Hutchinson, J J Hsuan, N F Totty, O Truong, A K Soutar, P N Hawkins, M Bruguera, J Caballería, M Solé, J M Campistol, M B Pepys.   

Abstract

We report a Spanish family with autosomal-dominant non-neuropathic hereditary amyloidosis with a unique hepatic presentation and death from liver failure, usually by the sixth decade. The disease is caused by a previously unreported deletion/insertion mutation in exon 4 of the apolipoprotein AI (apoAI) gene encoding loss of residues 60-71 of normal mature apoAI and insertion at that position of two new residues, ValThr. Affected individuals are heterozygous for this mutation and have both normal apoAI and variant molecules bearing one extra positive charge, as predicted from the DNA sequence. The amyloid fibrils are composed exclusively of NH2-terminal fragments of the variant, ending mainly at positions corresponding to residues 83 and 92 in the mature wild-type sequence. Amyloid fibrils derived from the other three known amyloidogenic apoAI variants are also composed of similar NH2-terminal fragments. All known amyloidogenic apoAI variants carry one extra positive charge in this region, suggesting that it may be responsible for their enhanced amyloidogenicity. In addition to causing a new phenotype, this is the first deletion mutation to be described in association with hereditary amyloidosis and it significantly extends the value of the apoAI model for investigation of molecular mechanisms of amyloid fibrillogenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675681      PMCID: PMC507363          DOI: 10.1172/JCI118725

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy.

Authors:  W C Nichols; R E Gregg; H B Brewer; M D Benson
Journal:  Genomics       Date:  1990-10       Impact factor: 5.736

2.  In vivo metabolism of a mutant apolipoprotein, apoA-IIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis.

Authors:  D J Rader; R E Gregg; M S Meng; J R Schaefer; L A Zech; M D Benson; H B Brewer
Journal:  J Lipid Res       Date:  1992-05       Impact factor: 5.922

3.  Differential tissue-specific expression of human apoA-I and apoA-II.

Authors:  T L Eggerman; J M Hoeg; M S Meng; A Tombragel; D Bojanovski; H B Brewer
Journal:  J Lipid Res       Date:  1991-05       Impact factor: 5.922

4.  Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene.

Authors:  C P Maury; J Kere; R Tolvanen; A de la Chapelle
Journal:  FEBS Lett       Date:  1990-12-10       Impact factor: 4.124

5.  Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30).

Authors:  G Holmgren; L Steen; J Ekstedt; C G Groth; B G Ericzon; S Eriksson; O Andersen; I Karlberg; G Nordén; M Nakazato
Journal:  Clin Genet       Date:  1991-09       Impact factor: 4.438

Review 6.  Normal and abnormal biology of the beta-amyloid precursor protein.

Authors:  D J Selkoe
Journal:  Annu Rev Neurosci       Date:  1994       Impact factor: 12.449

7.  Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg26.

Authors:  D M Vigushin; J Gough; D Allan; A Alguacil; B Penner; N M Pettigrew; G Quinonez; K Bernstein; S E Booth; D R Booth
Journal:  Q J Med       Date:  1994-03

8.  Site-specific methionine sulfoxide formation is the structural basis of chromatographic heterogeneity of apolipoproteins A-I, C-II, and C-III.

Authors:  A von Eckardstein; M Walter; H Holz; A Benninghoven; G Assmann
Journal:  J Lipid Res       Date:  1991-09       Impact factor: 5.922

9.  Isolation and characterization of the integral glycosaminoglycan constituents of human amyloid A and monoclonal light-chain amyloid fibrils.

Authors:  S R Nelson; M Lyon; J T Gallagher; E A Johnson; M B Pepys
Journal:  Biochem J       Date:  1991-04-01       Impact factor: 3.857

10.  Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis.

Authors:  A K Soutar; P N Hawkins; D M Vigushin; G A Tennent; S E Booth; T Hutton; O Nguyen; N F Totty; T G Feest; J J Hsuan
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

View more
  18 in total

1.  Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure.

Authors:  P Mangione; M Sunde; S Giorgetti; M Stoppini; G Esposito; L Gianelli; L Obici; L Asti; A Andreola; P Viglino; G Merlini; V Bellotti
Journal:  Protein Sci       Date:  2001-01       Impact factor: 6.725

Review 2.  A novel amyloidogenic variant of apolipoprotein AI: implications for a conformational change leading to cardiomyopathy.

Authors:  M T Walsh
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

3.  Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis.

Authors:  M M de Sousa; C Vital; D Ostler; R Fernandes; J Pouget-Abadie; D Carles; M J Saraiva
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

4.  Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I.

Authors:  Dorota Rowczenio; Ahmet Dogan; Jason D Theis; Julie A Vrana; Helen J Lachmann; Ashutosh D Wechalekar; Janet A Gilbertson; Toby Hunt; Simon D J Gibbs; Prayman T Sattianayagam; Jenny H Pinney; Philip N Hawkins; Julian D Gillmore
Journal:  Am J Pathol       Date:  2011-08-05       Impact factor: 4.307

Review 5.  Apolipoproteins and amyloid fibril formation in atherosclerosis.

Authors:  Chai Lean Teoh; Michael D W Griffin; Geoffrey J Howlett
Journal:  Protein Cell       Date:  2011-03-12       Impact factor: 14.870

6.  Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis.

Authors:  Julian D Gillmore; Helen J Lachmann; Dorota Rowczenio; Janet A Gilbertson; Cai-Hong Zeng; Zhi-Hong Liu; Lei-Shi Li; Ashutosh Wechalekar; Philip N Hawkins
Journal:  J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 10.121

Review 7.  Secondary intestinal amyloidosis presenting intractable hematochezia: a case report and literature review.

Authors:  So Hyun Kim; Jae Hwang Kim; Mi Jin Gu
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

8.  Tissue distribution, biochemical properties, and transmission of mouse type A AApoAII amyloid fibrils.

Authors:  Tatsumi Korenaga; Xiaoying Fu; Yanming Xing; Takatoshi Matsusita; Kazunao Kuramoto; Seigo Syumiya; Kazuhiro Hasegawa; Hironobu Naiki; Masaki Ueno; Tokuhiro Ishihara; Masanori Hosokawa; Masayuki Mori; Keiichi Higuchi
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

9.  Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene.

Authors:  Magdalena Eriksson; Stefan Schönland; Saniye Yumlu; Ute Hegenbart; Hanna von Hutten; Zarina Gioeva; Peter Lohse; Janine Büttner; Hartmut Schmidt; Christoph Röcken
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

10.  Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1.

Authors:  L Hamidi Asl; J J Liepnieks; K Hamidi Asl; T Uemichi; G Moulin; E Desjoyaux; R Loire; M Delpech; G Grateau; M D Benson
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.